LONDON, 31-8-2015 — /EuropaWire/ — Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of Cardiology (ESC) Congress 2015 in London, including five oral presentations. Data being presented will focus on the early management of Acute Coronary Syndromes (ACS) and long-term secondary prevention of atherothrombotic events in patients who have previously suffered a heart attack.
Presentation of the data, including sub-analyses of the BRILINTA® PEGASUS-TIMI 54 study, coincides with updates to the ESC guidelines on treatment of Non-ST Segment Elevation Myocardial Infarction patients, which will be presented at the congress on Sunday, 30 August. The updated guidelines will provide insight into long term dual antiplatelet therapy for patients with a history of heart attack.
The PEGASUS-TIMI 54 study sub-analyses will provide further understanding of the types of patients most likely to benefit from long-term treatment with BRILINTA. The data will also provide insight into the relationship between the time from a patient’s last treatment with P2Y12antiplatelet therapy and their risk of a subsequent heart attack, stroke or cardiovascular death as well as the effect of BRILINTA in this setting.
Elisabeth Björk, Vice President, Head of Cardiovascular and Metabolic Diseases, Global Medicines Development, AstraZeneca, said: “It is encouraging to see guideline updates recognise the continuing risk for patients more than one year after their heart attack and consider how this risk can be managed. We are looking forward to the presentation of the PEGASUS-TIMI 54 sub-analyses during the ESC Congress 2015 and to continuing the debate about the long-term use of dual antiplatelet therapy for these patients.”
In March 2015, based on the results of the PEGASUS-TIMI 54 study1, the US Food and Drug Administration (FDA) granted Priority Review for BRILINTA for the prevention of atherothrombotic events in patients who have previously experienced a heart attack.
Additional sub-analyses of the PEGASUS-TIMI 54 study also being presented at the ESC Congress 2015 include research into the relationship between renal function and risk of ischaemic and bleeding events, evaluated in a subset of high-risk patients with reduced renal function, and a gender comparison sub-analysis, assessing the relative safety and efficacy of ticagrelor in women versus men.
Other data highlights at the ESC Congress 2015 include:
• Data from the APOLLO real-world evidence study, exploring the impact of associated risk factors (such as age ≥65 years, diabetes, history of >1 prior myocardial infarction or renal disease) on the likelihood of recurrent cardiovascular events [abstract P2467], as well as long-term national healthcare costs post-heart attack [abstract 3662], will be featured as poster presentations on Sunday 30 August and Monday 31 August.
• Data from the ATLANTIC-H24 analysis, exploring the effect of pre-hospital versus
in-hospital administration of ticagrelor during the first 24 hours post-procedure, specifically among patients who underwent percutaneous coronary intervention (PCI), will feature on Monday 31 August, as part of the Clinical Trial Update II – Antiplatelet therapy session [abstract 3914].
• Two additional sub-analyses from ATLANTIC, exploring the study results according to gender [abstract P551] and within the French sub-population [abstract P556] will also be featured as poster presentations.
• Data from the SUPPORT study demonstrating the impact of a new interactive smartphone application on improving patient adherence and quality of life [abstract 6649] will be explored during a rapid fire abstract session on Wednesday 2 September.
• A VOYAGER meta-analysis examining the role of statin therapy, such as CRESTOR®(rosuvastatin) [poster P6465], in risk of atherosclerotic cardiovascular disease over a 10 year period will be presented in a poster session on Tuesday 1 September.
ASTRAZENECA ABSTRACTS TO BE FEATURED AT THE ESC CONGRESS 2015
Abstract #, Title and Author
|
Time (BST) / Session
|
---|---|
BRILINTA abstracts
|
|
Abstract P551
Worse short-term outcome for women with STEMI. Insights from the ATLANTIC study
Swahn E, et al
|
Saturday 29 August
11:00 – 16:00
Poster session 1: Infarction acute phase STEMI II
|
Abstract P556
Pre-hospital ticagrelor in ST-segment elevation myocardial infarction: the French subgroup analysis of the ATLANTIC study
Cayla G, et al
|
Saturday 29 August
11:00 – 16:00
Poster session 1: Infarction acute phase STEMI III
|
Abstract P1115
Dual anti-thrombotic effects of ticagrelor on Arterial Thrombosis: an anti-platelet agent with anti-coagulant properties
Reiner MF, et al
|
Sunday 30 August
Moderated poster presentation 10:34 – 10:42
Session: Clinical impact and modulation of endothelial (dys)function
|
Abstract P2463
High event rate in patients with acute coronary syndromes and atrial fibrillation: Results from the prospective EPICOR Registry
Zeymer U, et al
|
Sunday 30 August
14:00 – 18:00
Poster session 3: STEMI I
|
Abstract 3032
Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: Insights from the PEGASUS-TIMI 54 trial
Magnani G, et al
|
Monday 31 August
Oral presentation 09:24 – 09:41
Session: Antithrombotic drugs – An ongoing research
|
Abstract P3317
The efficacy and safety of ticagrelor in women versus men with a prior myocardial infarction: Insights from the PEGASUS-TIMI 54 trial
O’Donoghue M, et al
|
Monday 31 August
10:00 – 11:00
Best posters session 4
|
Abstract P3318
Ticagrelor 60 mg twice-daily provides effective platelet inhibition in patients with prior myocardial infarction – the PEGASUS-TIMI 54 platelet function substudy
Storey R, et al
|
Monday 31 August
10:00 – 11:00
Best posters session 4
|
Abstract 3914
Effect of pre-hospital ticagrelor in STEMI patients in the first 24 hours after primary PCI: The ATLANTIC-H24 analysis
Montalescot G, et al
|
Monday 31 August
Rapid fire abstract 14:15 – 14:30
Session: Clinical Trial Update II – Antiplatelet therapy
|
Abstract 3918
Ischemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal
Bonaca MP, et al
|
Monday 31 August
Oral presentation 15:15 – 15:30
Session: Clinical Trial Update II – Antiplatelet therapy
|
ACS abstracts
|
|
Abstract P172
Biomarker-based prediction model for recurrent ischemic events in revascularized patients with acute coronary syndromes
Lindholm D, et al
|
Saturday 29 August
Moderated poster presentation 12:38 – 12:47
Session: Post infarction period
|
Abstract P2467
Cardiovascular risk in post-myocardial infarction patients: Nationwide real-world data on distribution and impact of combination of risk factors in a real-life setting
Jernberg T, et al
|
Sunday 30 August
14:00 – 18:00
Poster session 3: STEMI I
|
Abstract 3662
Long-term healthcare costs after myocardial infarction in a clinical practice setting in Sweden; results from a contemporary nationwide registry study
Janzon M, et al
|
Monday 31 August
08:30 – 12:30
Poster session 4: Improvement of medical care in cardiovascular patients: social and economic issues
|
Abstract 3030
Effect of Time to interventional treatment on NSTE-ACS Outcomes in PLATO
Pollack C, et al
|
Monday 31 August
Oral presentation 08:50 – 09:07
Session: Antithrombotic drugs – An ongoing research
|
Abstract 3031
Treatment and long-term results of acute coronary syndrome (ACS) in patients on chronic oral anticoagulants (OAC): data from the EPICOR (NCT01171404) study
Stepinska J, et al
|
Monday 31 August
Oral presentation 09:07 – 09:24
Session: Antithrombotic drugs – An ongoing research
|
Abstract P3319
Differences in dual antiplatelet treatment for acute coronary syndrome patients undergoing PCI or not: a Danish nationwide population-based cohort study
Gislason G, et al
|
Monday 31 August
10:00 – 11:00
Best posters session 4
|
Abstract P5340
Prognostic value of elevated high-sensitivity cardiac troponin T levels in patients with stable coronary artery disease
Biener M, et al
|
Tuesday 1 September
08:30 – 12:30
Poster session 6: Coronary artery disease and comorbidities I
|
Abstract 4972
Treatment pattern of dual antiplatelet therapy in 104,012 patients with acute coronary syndrome; a Swedish nationwide population based cohort study
Angeras O, et al
|
Tuesday 1 September
Rapid fire abstract 08:39 – 08:48
Session: Flash news on antithrombotics
|
Abstract 4975
Balancing the risk of ischaemic and bleeding events in ACS
Ducrocq G, et al
|
Tuesday 1 September
Rapid fire abstract 08:57 – 09:06
Session: Flash news on antithrombotics
|
Abstract 6649
Effects of interactive patient support with a smartphone app on drug adherence and lifestyle changes in myocardial infarction patients
Varenhorst C, et al
|
Wednesday 2 September
Rapid fire abstract 08:57 – 09:06
Session: Cardiovascular prevention: what works for whom?
|
Abstract 6654
Health outcomes and platelet-aggregation inhibition after acute myocardial infarction in clinical practice. Findings from the PIPER study
Esposti LD, et al
|
Wednesday 2 September
Rapid fire abstract 09:42 – 09:51
Session: Cardiovascular prevention: what works for whom?
|
CRESTOR abstracts
|
|
Abstract P6465
Estimating the reduction in 10-year atherosclerotic cardiovascular disease risk with statin therapy: a VOYAGER meta-analysis
Karlson B, et al
|
Tuesday 1 September
14:00 – 18:00
Poster session 7: Surveillance of risk factors and interventions
|
Abstract P6551
YKL-40 in chronic heart failure: Analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA)
Kanwal AF, et al
|
Tuesday 1 September
14:00 – 18:00
Poster session 7: Prognosis II
|
NOTES TO EDITORS
1 Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791-800.
About BRILINTA®
BRILINTA is a direct-acting, selective and reversibly binding P2Y12 receptor antagonist in a chemical class called cyclo-pentyl-triazolo-pyrimidines (CPTPs). BRILINTA works by inhibiting platelet activation.
BRILINTA (90mg) is indicated to reduce the rate of thrombotic cardiovascular (CV) events in patients with ACS (unstable angina [UA], non–ST-elevation myocardial infarction [NSTEMI], or ST-elevation myocardial infarction [STEMI]). BRILINTA has been shown to reduce the rate of a combined end point of CV death, MI, or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with percutaneous coronary intervention, it also reduces the rate of stent thrombosis.
BRILINTA is a registered trademark of the AstraZeneca group.
About the PEGASUS TIMI-54 study
PEGASUS-TIMI 54 (PrEvention with TicaGrelor of SecondAry Thrombotic Events in High-RiSk Patients with Prior AcUte Coronary Syndrome – Thrombolysis In Myocardial Infarction Study Group) is one of AstraZeneca’s largest ever outcomes trials with more than 21,000 patients from over 1,100 sites in 31 countries in Europe, the Americas, Africa and Australia/Asia. It was conducted in collaboration with the Thrombolysis in Myocardial Infarction (TIMI) Study Group from Brigham and Women’s Hospital (Boston, MA, USA).
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:www.astrazeneca.com
CONTACTS
Media Enquiries
Name | Region | Phone Number |
---|---|---|
Esra Erkal-Paler | UK/Global | +44 20 7604 8030 |
Vanessa Rhodes | UK/Global | +44 20 7604 8037 |
Ayesha Bharmal | UK/Global | +44 20 7604 8034 |
Jacob Lund | Sweden | +46 8 553 260 20 |
Michele Meixell | US | + 1 302 885 6351 |
Investor Enquiries
UK
Name | Area | Phone Number | Mobile Phone Number |
---|---|---|---|
Thomas Kudsk Larsen | +44 20 7604 8199 | +44 7818 524185 | |
Eugenia Litz | RIA | +44 20 7604 8233 | +44 7884 735627 |
Nick Stone | CVMD | +44 17 6326 3994 | +44 7717 618834 |
Karl Hård | Oncology | +44 20 7604 8123 | +44 7789 654364 |
Craig Marks | ING | +44 20 7604 8591 | +44 7881 615764 |
Christer Gruvris | +44 20 7604 8126 | +44 7827 836825 |
US
Name | Area | Phone Number | Mobile Phone Number |
---|---|---|---|
Dial / Toll-Free | +1 301 398 3251 | +1 866 381 7277 |
Key: RIA – Respiratory, Inflammation and Autoimmunity, CVMD – Cardiovascular and Metabolic Disease, ING – Infection, Neuroscience and Gastrointestinal
- Astor Asset Management 3 Ltd: Salinas Pliego Incumple Préstamo de $110 Millones USD y Viola Regulaciones Mexicanas
- Astor Asset Management 3 Ltd: Salinas Pliego Verstößt gegen Darlehensvertrag über 110 Mio. USD und Mexikanische Wertpapiergesetze
- ChargeEuropa zamyka rundę finansowania, której przewodził fundusz Shift4Good tym samym dokonując historycznej francuskiej inwestycji w polski sektor elektromobilności
- Strengthening EU Protections: Robert Szustkowski calls for safeguarding EU citizens’ rights to dignity
- Digi Communications NV announces the release of H1 2024 Financial Results
- Digi Communications N.V. announces that conditional stock options were granted to a director of the Company’s Romanian Subsidiary
- Digi Communications N.V. announces Investors Call for the presentation of the H1 2024 Financial Results
- Digi Communications N.V. announces the conclusion of a share purchase agreement by its subsidiary in Portugal
- Digi Communications N.V. Announces Rating Assigned by Fitch Ratings to Digi Communications N.V.
- Digi Communications N.V. announces significant agreements concluded by the Company’s subsidiaries in Spain
- SGW Global Appoints Telcomdis as the Official European Distributor for Motorola Nursery and Motorola Sound Products
- Digi Communications N.V. announces the availability of the instruction regarding the payment of share dividend for the 2023 financial year
- Digi Communications N.V. announces the exercise of conditional share options by the executive directors of the Company, for the year 2023, as approved by the Company’s Ordinary General Shareholders’ Meetings from 18th May 2021 and 28th December 2022
- Digi Communications N.V. announces the granting of conditional stock options to Executive Directors of the Company based on the general shareholders’ meeting approval from 25 June 2024
- Digi Communications N.V. announces the OGMS resolutions and the availability of the approved 2023 Annual Report
- Czech Composer Tatiana Mikova Presents Her String Quartet ‘In Modo Lidico’ at Carnegie Hall
- SWIFTT: A Copernicus-based forest management tool to map, mitigate, and prevent the main threats to EU forests
- WickedBet Unveils Exciting Euro 2024 Promotion with Boosted Odds
- Museum of Unrest: a new space for activism, art and design
- Digi Communications N.V. announces the conclusion of a Senior Facility Agreement by companies within Digi Group
- Digi Communications N.V. announces the agreements concluded by Digi Romania (formerly named RCS & RDS S.A.), the Romanian subsidiary of the Company
- Green Light for Henri Hotel, Restaurants and Shops in the “Alter Fischereihafen” (Old Fishing Port) in Cuxhaven, opening Summer 2026
- Digi Communications N.V. reports consolidated revenues and other income of EUR 447 million, adjusted EBITDA (excluding IFRS 16) of EUR 140 million for Q1 2024
- Digi Communications announces the conclusion of Facilities Agreements by companies from Digi Group
- Digi Communications N.V. Announces the convocation of the Company’s general shareholders meeting for 25 June 2024 for the approval of, among others, the 2023 Annual Report
- Digi Communications NV announces Investors Call for the presentation of the Q1 2024 Financial Results
- Digi Communications intends to propose to shareholders the distribution of dividends for the fiscal year 2023 at the upcoming General Meeting of Shareholders, which shall take place in June 2024
- Digi Communications N.V. announces the availability of the Romanian version of the 2023 Annual Report
- Digi Communications N.V. announces the availability of the 2023 Annual Report
- International Airlines Group adopts Airline Economics by Skailark ↗️
- BevZero Spain Enhances Sustainability Efforts with Installation of Solar Panels at Production Facility
- Digi Communications N.V. announces share transaction made by an Executive Director of the Company with class B shares
- BevZero South Africa Achieves FSSC 22000 Food Safety Certification
- Digi Communications N.V.: Digi Spain Enters Agreement to Sell FTTH Network to International Investors for Up to EUR 750 Million
- Patients as Partners® Europe Announces the Launch of 8th Annual Meeting with 2024 Keynotes and Topics
- driveMybox continues its international expansion: Hungary as a new strategic location
- Monesave introduces Socialised budgeting: Meet the app quietly revolutionising how users budget
- Digi Communications NV announces the release of the 2023 Preliminary Financial Results
- Digi Communications NV announces Investors Call for the presentation of the 2023 Preliminary Financial Results
- Lensa, един от най-ценените търговци на оптика в Румъния, пристига в България. Първият шоурум е открит в София
- Criando o futuro: desenvolvimento da AENO no mercado de consumo em Portugal
- Digi Communications N.V. Announces the release of the Financial Calendar for 2024
- Customer Data Platform Industry Attracts New Participants: CDP Institute Report
- eCarsTrade annonce Dirk Van Roost au poste de Directeur Administratif et Financier: une décision stratégique pour la croissance à venir
- BevZero Announces Strategic Partnership with TOMSA Desil to Distribute equipment for sustainability in the wine industry, as well as the development of Next-Gen Dealcoholization technology
- Digi Communications N.V. announces share transaction made by a Non-Executive Director of the Company with class B shares
- Digi Spain Telecom, the subsidiary of Digi Communications NV in Spain, has concluded a spectrum transfer agreement for the purchase of spectrum licenses
- Эксперт по торговле акциями Сергей Левин запускает онлайн-мастер-класс по торговле сырьевыми товарами и хеджированию
- Digi Communications N.V. announces the conclusion by Company’s Portuguese subsidiary of a framework agreement for spectrum usage rights
- North Texas Couple Completes Dream Purchase of Ouray’s Iconic Beaumont Hotel
- Предприниматель и филантроп Михаил Пелег подчеркнул важность саммита ООН по Целям устойчивого развития 2023 года в Нью-Йорке
- Digi Communications NV announces the release of the Q3 2023 Financial Results
- IQ Biozoom Innovates Non-Invasive Self-Testing, Empowering People to Self-Monitor with Laboratory Precision at Home
- BevZero Introduces Energy Saving Tank Insulation System to Europe under name “BevClad”
- Motorvision Group reduces localization costs using AI dubbing thanks to partnering with Dubformer
- Digi Communications NV Announces Investors Call for the Q3 2023 Financial Results
- Jifiti Granted Electronic Money Institution (EMI) License in Europe
- Предприниматель Михаил Пелег выступил в защиту образования и грамотности на мероприятии ЮНЕСКО, посвящённом Международному дню грамотности
- VRG Components Welcomes New Austrian Independent Agent
- Digi Communications N.V. announces that Digi Spain Telecom S.L.U., its subsidiary in Spain, and abrdn plc have completed the first investment within the transaction having as subject matter the financing of the roll out of a Fibre-to-the-Home (“FTTH”) network in Andalusia, Spain
- Продюсер Михаил Пелег, как сообщается, работает над новым сериалом с участием крупной голливудской актрисы
- Double digit growth in global hospitality industry for Q4 2023
- ITC Deploys Traffic Management Solution in Peachtree Corners, Launches into United States Market
- Cyviz onthult nieuwe TEMPEST dynamische controlekamer in Benelux, Nederland
- EU-Funded CommuniCity Launches its Second Open Call
- Astrologia pode dar pistas sobre a separação de Sophie Turner e Joe Jonas
- La astrología puede señalar las razones de la separación de Sophie Turner y Joe Jonas
- Empowering Europe against infectious diseases: innovative framework to tackle climate-driven health risks
- Montachem International Enters Compostable Materials Market with Seaweed Resins Company Loliware
- Digi Communications N.V. announces that its Belgian affiliated companies are moving ahead with their operations
- Digi Communications N.V. announces the exercise of conditional share options by an executive director of the Company, for the year 2022, as approved by the Company’s Ordinary General Shareholders’ Meeting from 18 May 2021
- Digi Communications N.V. announces the availability of the instruction regarding the payment of share dividend for the 2022 financial year
- Digi Communications N.V. announces the availability of the 2022 Annual Report
- Digi Communications N.V. announces the general shareholders’ meeting resolutions from 18 August 2023 approving amongst others, the 2022 Annual Accounts
- Русские эмигранты усиливают призывы «Я хочу, чтобы вы жили» через искусство
- BevZero Introduces State-of-the-Art Mobile Flash Pasteurization Unit to Enhance Non-Alcoholic Beverage Stability at South Africa Facility
- Russian Emigrés Amplify Pleas of “I Want You to Live” through Art
- Digi Communications NV announces the release of H1 2023 Financial Results
- Digi Communications NV Announces Investors Call for the H1 2023 Financial Results
- Digi Communications N.V. announces the convocation of the Company’s general shareholders meeting for 18 August 2023 for the approval of, among others, the 2022 Annual Report
- “Art Is Our Weapon”: Artists in Exile Deploy Their Talents in Support of Peace, Justice for Ukraine
- Digi Communications N.V. announces the availability of the 2022 Annual Financial Report
- “AmsEindShuttle” nuevo servicio de transporte que conecta el aeropuerto de Eindhoven y Ámsterdam
- Un nuovo servizio navetta “AmsEindShuttle” collega l’aeroporto di Eindhoven ad Amsterdam
- Digi Communications N.V. announces the conclusion of an amendment agreement to the Facility Agreement dated 26 July 2021, by the Company’s Spanish subsidiary
- Digi Communications N.V. announces an amendment of the Company’s 2023 financial calendar
- iGulu F1: Brewing Evolution Unleashed
- Почему интерактивная «Карта мира» собрала ключевые антивоенные сообщества россиян по всему миру и становится для них важнейшим инструментом
- Hajj Minister meets EU ambassadors to Saudi Arabia
- Online Organizing Platform “Map of Peace” Emerges as Key Tool for Diaspora Activists
- Digi Communications N.V. announces that conditional stock options were granted to executive directors of the Company based on the general shareholders’ meeting approval from 18 May 2021
- Digi Communications N.V. announces the release of the Q1 2023 financial results
- AMBROSIA – A MULTIPLEXED PLASMO-PHOTONIC BIOSENSING PLATFORM FOR RAPID AND INTELLIGENT SEPSIS DIAGNOSIS AT THE POINT-OF-CARE
- Digi Communications NV announces Investors Call for the Q1 2023 Financial Results presentation
- Digi Communications N.V. announces the amendment of the Company’s 2023 financial calendar
- Digi Communications N.V. announces the conclusion of two Facilities Agreements by the Company’s Romanian subsidiary
- Digi Communications N.V. announces the conclusion of a Senior Facility Agreement by the Company’s Romanian subsidiary
- Patients as Partners Europe Returns to London and Announces Agenda Highlights
- GRETE PROJECT RESULTS PRESENTED TO TEXTILE INDUSTRY STAKEHOLDERS AT INTERNATIONAL CELLULOSE FIBRES CONFERENCE
- Digi Communications N.V. announces Digi Spain Telecom S.L.U., its subsidiary in Spain, entered into an investment agreement with abrdn to finance the roll out of a Fibre-to-the-Home (FTTH) network in Andalusia, Spain
- XSpline SPA / University of Linz (Austria): the first patient has been enrolled in the international multicenter clinical study for the Cardiac Resynchronization Therapy DeliveRy guided by non-Invasive electrical and VEnous anatomy assessment (CRT-DRIVE)
- Franklin Junction Expands Host Kitchen® Network To Europe with Digital Food Hall Pioneer Casper
- Unihertz a dévoilé un nouveau smartphone distinctif, Luna, au MWC 2023 de Barcelone
- Unihertz Brachte ein Neues, Markantes Smartphone, Luna, auf dem MWC 2023 in Barcelona
- Editor's pick archive....